**To:** Vendinello, Lynn[Vendinello.Lynn@epa.gov]

Cc: Doa, Maria[Doa.Maria@epa.gov]; Krasnic, Toni[krasnic.toni@epa.gov]; Kramek,

Niva[kramek.niva@epa.gov]

From: Wolf, Joel

**Sent:** Tue 11/21/2017 5:20:36 PM

Subject: RE: TCE

Good question. I'd go with Hans and Chris B.

-----

Joel Wolf

Chief, Existing Chemicals Branch

OCSPP/OPPT/CCD

US Environmental Protection Agency

WJC East, Room 4121A

202.564.0432, wolf.joel@epa.gov

From: Vendinello, Lynn

Sent: Tuesday, November 21, 2017 12:19 PM

**To:** Wolf, Joel < Wolf.Joel@epa.gov>

Cc: Doa, Maria < Doa. Maria @epa.gov>; Krasnic, Toni < krasnic.toni @epa.gov>; Kramek, Niva

<kramek.niva@epa.gov>

Subject: RE: TCE

Perfect, I will forward onto Jeff and cc the special assistants. Anyone in particular for this topic?

Lynn Vendinello

**Deputy Director** 

**Chemical Control Division** 

Office of Pollution Prevention and Toxics

US. EPA

202-566-0514

From: Wolf, Joel

Sent: Tuesday, November 21, 2017 12:18 PM

To: Vendinello, Lynn < Vendinello. Lynn@epa.gov >

Cc: Doa, Maria < Doa. Maria@epa.gov >; Krasnic, Toni < krasnic.toni@epa.gov >; Kramek, Niva

<a href="mailto:<a href="mailto:kramek.niva@epa.gov">kramek.niva@epa.gov</a>>

Subject: RE: TCE

Hi Lynn,

## **Ex. 5 - Deliberative Process**

Attached is a V3. Thanks, Joel
Joel Wolf
Chief, Existing Chemicals Branch
OCSPP/OPPT/CCD
US Environmental Protection Agency
WJC East, Room 4121A
202.564.0432, wolf.joel@epa.gov

From: Vendinello, Lynn

Sent: Tuesday, November 21, 2017 11:48 AM

**To:** Wolf, Joel < <u>Wolf.Joel@epa.gov</u>>

Cc: Doa, Maria < Doa. Maria@epa.gov >; Krasnic, Toni < krasnic.toni@epa.gov >; Kramek, Niva

< kramek.niva@epa.gov>

Subject: RE: TCE

Thanks Joel.

Ex. 5 - Deliberative Process

## Ex. 5 - Deliberative Process

Lynn Vendinello

**Deputy Director** 

**Chemical Control Division** 

Office of Pollution Prevention and Toxics

US. EPA

202-566-0514

From: Wolf, Joel

**Sent:** Tuesday, November 21, 2017 11:41 AM **To:** Vendinello, Lynn < Vendinello.Lynn@epa.gov >

Cc: Doa, Maria < Doa. Maria @epa.gov>; Krasnic, Toni < krasnic.toni @epa.gov>; Kramek, Niva

< kramek.niva@epa.gov>

Subject: FW: TCE

Hi Lynn,

Per the below email, Michael Dourson is looking for additional meeting on the site visit that

version (labeled V2) and the redline version with responses to Maria's comments.
Maria indicated that this should go up through Jeff to Michael. If you are okay with it, just the clean version should go to Jeff.
Thanks, Joel
Joel Wolf
Chief, Existing Chemicals Branch
OCSPP/OPPT/CCD
US Environmental Protection Agency
WJC East, Room 4121A
202.564.0432, wolf.joel@epa.gov
From: Dourson, Michael Sent: Friday, November 17, 2017 6:30 PM To: Krasnic, Toni < krasnic.toni@epa.gov> Cc: Beck, Nancy < Beck.Nancy@epa.gov>; Bertrand, Charlotte < Bertrand.Charlotte@epa.gov>; Morris, Jeff < Morris.Jeff@epa.gov>; Doa, Maria < Doa.Maria@epa.gov>; Wolf, Joel < Wolf.Joel@epa.gov> Subject: Re: TCE
Toni
Thanks!

Michael Sent from my iPhone On Nov 17, 2017, at 12:57 PM, Krasnic, Toni < krasnic.toni@epa.gov > wrote: Hi Michael, Thank you for your interest in this topic. We'll pull together additional information on this visit and will send it to you once it's compiled. Thanks, Toni Krasnic **Existing Chemicals Branch** EPA/OCSPP/OPPT/CCD/ECB WJC East, 4134D | (202) 564-0984 From: Dourson, Michael Sent: Friday, November 17, 2017 12:37 PM To: Krasnic, Toni < krasnic.toni@epa.gov> Cc: Beck, Nancy < Beck. Nancy@epa.gov >; Bertrand, Charlotte <<u>Bertrand.Charlotte@epa.gov</u>>; Morris, Jeff < Morris.Jeff@epa.gov> Subject: TCE

18cv794 NRDC v EPA

Dear Toni Krasnic

I would be interested in more information regarding this topic.

Visit at Integer facility on use of TCE in vapor degreasing in the manufacture of medical devices: On October 19, 2017, CCD, CESSD, and RAD staff visited Integer's facility in Minneapolis, MN. Integer was formed from the merger of Greatbatch, Lake Region Medical, and Electrochem, and specializes in the design and development of medical devices and power solutions for the medical and non-medical markets. EPA toured Integer's facility where they make various medical devices, for a demonstration of open-top vapor degreasing, spray degreasing, enclosed vapor degreasing, and aqueous degreasing. Integer also provided a tour of their manufacturing process of medical devices and showed samples of their actual medical products. Additionally, they discussed the research and testing they've done on non-TCE alternatives and argued that there are no effective alternatives available that can clean all of the medical devices they produce and are compatible with lubricants they use. Validation by FDA of new cleaning process in medical device manufacturing process, which typically takes about 3 years, was also highlighted as a major challenge to transitioning to TCE alternatives

Thanks!
Michael
L. Dourson, PhD., DABT, FATS, FSRA
Senior Advisor to the Administrator
U.S. Environmental Protection Agency
dourson.michael@epa.gov
202-564-2463

www.epa.gov